Recent Updates
Recently added Catalysts
EW Positive Sentiment

Edwards Lifesciences Reports Third Quarter Results

Wednesday, November 4, 2026 BiopharmaWatch Research 1 min read
Add on Google
Key Takeaway: Edwards Lifesciences reported strong financial results for Q3 2026, with sales reaching $1.72 billion, a 10.5% increase. The company saw notable growth in TAVR and TMTT sales, with TMTT sales up 44.0%. Adjusted EPS rose by 19% from the previous year, reflecting positive performance.

Market Sentiment Analysis

POSITIVE FACTORS

  • Q3 sales increased by 10.5% to $1.72 billion.
  • TAVR sales rose by 8.0% to $1.24 billion.
  • TMTT sales surged 44.0% to $207 million.
  • Adjusted EPS grew by 19% compared to the prior year.

Full Press Release Details

IRVINE, Calif.--(BUSINESS WIRE)--Edwards Lifesciences (NYSE: EW) today reported financial results for the quarter ended September 30, 2026. Q3 Financial Highlights Q3 sales grew 10.5% to $1.72 billion1, constant currency2 sales grew 11.2% Q3 TAVR sales grew 8.0% to $1.24 billion1, constant currency2 sales grew 8.8% Q3 TMTT sales grew 44.0% to $207 million1,3, constant currency2 sales grew 45.6%3 Q3 EPS of $0.531; adjusted2 EPS of $0.801 which grew 19% versus prior year 2026 Outlook Increasing t

Frequently Asked Questions

What were Edwards Lifesciences' Q3 sales figures?

Q3 sales reached $1.72 billion, a 10.5% increase.

How much did TAVR sales grow in Q3?

TAVR sales grew 8.0% to $1.24 billion.

What was the growth percentage for TMTT sales?

TMTT sales surged 44.0% to $207 million.

What was the adjusted EPS for Q3?

The adjusted EPS was $0.80, a 19% increase year-over-year.

ShareAdd on Google
Tags: EW Edwards Lifesciences Q3 results TAVR sales TMTT sales financial results
Last updated: Nov 4, 2026

Biotech snapshot

Cash runway
$4253M liquidity · $0M/mo burn
Low dilution risk